Suven Life Sciences has been granted one product patent from New Zealand and one patent from Norway corresponding to the new chemical entities (NCEs).

The patents are for treatment of disorders associated with Neurodegenerative diseases and are valid through 2034 and 2027.

Further, the granted claims of the patents include the class of selective 5HT 6 compounds and are being developed as therapeutic agents for depressive disorders and for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia respectively.

Read EquityPandit’s Technical Analysis of Indian Stock Market